These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 27789659)

  • 1. Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.
    Murata K; Asano M; Matsumoto A; Sugiyama M; Nishida N; Tanaka E; Inoue T; Sakamoto M; Enomoto N; Shirasaki T; Honda M; Kaneko S; Gatanaga H; Oka S; Kawamura YI; Dohi T; Shuno Y; Yano H; Mizokami M
    Gut; 2018 Feb; 67(2):362-371. PubMed ID: 27789659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus Infection.
    Murata K; Tsukuda S; Suizu F; Kimura A; Sugiyama M; Watashi K; Noguchi M; Mizokami M
    Hepatology; 2020 May; 71(5):1533-1545. PubMed ID: 31529730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
    Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
    Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
    J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients.
    Lin CC; Bair MJ; Chen CJ; Lee KH; Chen MJ; Liu CY; Chang CW; Hu KC; Liou TC; Lin SC; Wang HY; Chu CH; Shih SC; Wang TE
    Kaohsiung J Med Sci; 2016 Jan; 32(1):10-5. PubMed ID: 26853169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
    Buster EH; Schalm SW; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma.
    Tsai HW; Lin YJ; Wu HC; Chang TT; Wu IC; Cheng PN; Yen CJ; Chan SH; Huang W; Su IJ
    Oncotarget; 2016 May; 7(19):27724-34. PubMed ID: 27027237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
    Boglione L; D'Avolio A; Cariti G; Gregori G; Burdino E; Baietto L; Cusato J; Ghisetti V; De Rosa FG; Di Perri G
    Liver Int; 2013 Apr; 33(4):580-5. PubMed ID: 23311449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
    Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
    Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
    J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible biological mechanisms of entecavir versus tenofovir disoproxil fumarate on reducing the risk of hepatocellular carcinoma.
    Murata K; Mizokami M
    J Gastroenterol Hepatol; 2023 May; 38(5):683-691. PubMed ID: 36918402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there an association between the measurement of qualitative HBsAg and virologic response in chronic HBV infection?
    Altinbas A; Aktas B; Basar O; Yüksel O; Ekiz F; Yilmaz B; Coban S
    Ann Hepatol; 2012; 11(3):320-5. PubMed ID: 22481449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: a head-to-head study.
    Yu S; Zhou Q; Zhao XM; Yuan M; Wang CT; Cheng XG; Zhang ZH; Li X
    Saudi J Gastroenterol; 2014; 20(6):350-5. PubMed ID: 25434315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir
    Rodríguez M; Pascasio JM; Fraga E; Fuentes J; Prieto M; Sánchez-Antolín G; Calleja JL; Molina E; García-Buey ML; Blanco MÁ; Salmerón J; Bonet ML; Pons JA; González JM; Casado MÁ; Jorquera F;
    World J Gastroenterol; 2017 Nov; 23(41):7459-7469. PubMed ID: 29151700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.
    Vincenti D; Piselli P; Solmone M; D'Offizi G; Capobianchi MR; Menzo S
    Antiviral Res; 2017 Jul; 143():62-68. PubMed ID: 28322924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures.
    Zhang Q; Han T; Nie CY; Ha FS; Liu L; Liu H
    J Med Virol; 2015 Jun; 87(6):1013-21. PubMed ID: 25716029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
    Lim YS; Lee TH; Heo NY; Shim JH; Lee HC; Suh DJ
    Antivir Ther; 2012; 17(1):53-60. PubMed ID: 22267469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.